Vascular Closure Clinical Trial
Official title:
Patient Comfort Study With Vascular Closure: Mynx vs. Angio-Seal Evolution
The purpose of this research study is to collect information on the amount of discomfort patients experience with one of two different vascular blood vessel closure devices, the MynxM5 Vascular Closure Device and the Angio-Seal Evolution Vascular Closure Device.
The traditional, standard technique of achieving femoral artery hemostasis following
diagnostic and interventional catheterization procedures requires compression methods such
as manual pressure or clamps held at the puncture site for 10 to 30 minutes, or even longer
depending on sheath size and anticoagulation status. This traditional method can be
associated with patient discomfort as well as prolonged bed rest, ambulation and hospital
discharge.
Over the past decade, Vascular Closure Devices (VCDs), which include collagen hemostasis
devices, percutaneous suture-mediated closure devices and metallic clips, have emerged as a
novel means for reducing time to hemostasis and ambulation following catheterization
procedures performed utilizing femoral arterial access. Previous studies with commercially
available VCDs have shown that the reduction in time to hemostasis and time to ambulation
and discharge have also led to increased patient satisfaction over manual compression.
The MynxM5 Vascular Closure Device received FDA approval on April 8, 2009. Like the Mynx
6/7F Vascular Closure Device, which received FDA approval on May 16, 2007, both are designed
to achieve femoral artery hemostasis via delivery of an extravascular, water-soluble
synthetic sealant which expands upon contact with subcutaneous fluids to seal the
arteriotomy. In theory, the lack of pressure needed to clamp, suture, clip or cinch, which
is required with intravascular closure devices, may provide an advantage in regards to
increased patient comfort during closure device deployment when using the Mynx.
Although VCDs have demonstrated an increase in patient comfort and satisfaction over manual
compression, little data exists regarding patient comfort when comparing different closure
devices. This study is designed to evaluate patient comfort between the MynxM5 and
Angio-Seal Evolution Vascular Closure Devices.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05335525 -
Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)
|
||
Completed |
NCT01858636 -
Post-Market Study of the St. Jude Medical Angio-Seal™ V-Twist Integrated Platform (VIP) Vascular Closure Device
|
||
Active, not recruiting |
NCT04203329 -
AMBULATE Same Day Discharge Registry
|
||
Completed |
NCT00842179 -
Groin Complications Post Percutaneous Coronary Intervention Using Either Manual Compression or PERCLOSE Device
|
N/A | |
Not yet recruiting |
NCT06358157 -
The Ladera Large Bore Closure Feasibility Study
|
N/A | |
Completed |
NCT05027698 -
Post-Market Clinical Investigation of the FemoSeal™ VCS: A Prospective, Multi-Center Observational European Study
|
||
Completed |
NCT03756558 -
Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System
|
N/A | |
Not yet recruiting |
NCT05822804 -
Safety and Efficacy of the Vascular Closure Device (Tonbridge) in Hemostasis Treatment of Femoral Artery Puncture
|
N/A |